For the past twenty-five years the transvenouscatheter electrophysiologic (EP) study has occupied a central position in the investigation and management of patients with ventricular tachycardia (VT) and ventricular fibrillation (VF) [1,2]. During that time, most of the advances made relative to our understanding of the mechanisms and of the therapeutics of VT/VF involved the EP study. More recently, the spectacular success of the implantable cardioverter defibrillator (ICD) has reduced the number of indications for an EP study in patients with VT/VF. Although, the EP study still represents a value-added procedure for most patients with a propensity to VT/VF [3], the number of EP studies performed for this purpose is decreasing. The purpose of this update is to highlight recent advances in the techniques and application of the EP study in patients with chronic ischemic heart disease.
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Diagnostic EP Study-Techniques
The procedural details of an EP study for patients with VT/VF have not changed substantially over the past decade and no recent studies have advanced our knowledge in this area. Although no "standard" VT/VF programmed stimulation protocol has been defined, many laboratories have adopted the stimulation protocol of the Electrophysiologic Study Versus Electrocardiographic monitoring (ESVEM) study [4] . The steps in that protocol are summarized in Table 1 . The rationale for the ESVEM stimulation protocol includes delaying the use of triple ventricular extrastimuli as long as possible to maximize the yield of clinically-relevant VT while minimizing the probability of induction of potentially irrelevant polymorphic VT or VF. When this stimulation protocol fails to induce VT/VF, some have advocated the use of bursts of rapid ventricular pacing, long-short extrastimulation techniques, greater numbers of extrastimuli, left ventricular stimulation, or stimulation after the administration of isoproterenol. Aggressive stimulation protocols are best reserved for patients with documented monomorphic VT to permit its distinction from less specific polymorphic VT or VF that may be induced by aggressive stimulation.
Standards for the procedural details of a treatment-assessment EP study are even less well defined. Most laboratories will predict a therapy to be effective when completion of the entire stimulation protocol from that site which permitted reproducible VT/VF induction at the baseline study fails to induce VT/VF after therapy. The patient response criterion separating a suppressed VT/VF from a nonsuppressed VT/VF varies from 2 repetitive ventricular responses to less than 30 seconds of VT/VF. Nevertheless, most laboratories use a patient response cutoff between 5 and 16 ventricular responses. A randomized trial of use of less than 5 induced ventricular responses versus use of less than 16 induced ventricular responses in the definition of predicted effective antiarrhythmic drug therapy for patients with VT/VF has recently provided evidence supporting use of the more stringent criterion [5] . Other more assertive approaches to defining predicted-effective therapy include delivery of the full stimulation protocol at two RV sites, at both an RV and an LV site, during isoproterenol administration, and by rechecking the efficacy prediction by repeating the EP study on a different day.
Diagnostic EP Study-Indications
The advantages of performing a baseline EP study in patients presenting with VT/VF in the absence of a transient or reversible cause have been reviewed recently [3] . These advantages include identification of the initiating tachyarrhythmia in patients with VT/VF (which may actually have been a supraventricular tachyarrhythmia), identification of VT mechanisms readily amenable to catheter ablation (such as bundle branch reentrant RV apex/RV outflow tract Stimulation protocol: V 2 from RVA V 1 V 2 @ 600, 500, 400 msec from RVA V 1 V 2 V 3 @ 600, 500, 400 msec from RVA V 1 V 2 @ 600, 500, 400 msec from RVOT V 1 V 2 V 3 @ 600, 500, 400 msec from RVOT V 1 V 2 V 3 V 4 @ 600, 500, 400 msec from RVOT V 1 V 2 V 3 V 4 @ 600, 500, 400 msec from RVA Each extrastimuli setting repeated twice Abbreviations: RVA = right ventricular apex, RVOT = right ventricular outflow tract, V 1 = 8 to 12 paced ventricular depolarizations, V 2 = first ventricular extrastimulus, V 3 = second ventricular extrastimulus, V 4 = third ventricular extrastimulus.
VT), assessment of the response of a patient's VT to attempts at pace-termination (thereby assessing the applicability of a tiered-therapy implantable cardioverter defibrillator), evaluation of candidacy for specific approaches to VT/VF therapy (such as catheter ablation or electrosurgery), and continued enhancement of our understanding of the mechanisms and therapeutics of VT/VF. The advantages of a baseline EP study are most evident for patients with spontaneous VT. Good results have been recently reported for patients with documented VF that were treated with an ICD without first having been subjected to either an EP study or a trial of antiarrhythmic drug therapy [6] .
Therapeutic EP Study-Indications
The most common therapeutic use of the transvenous catheter EP study in patients with VT/VF is prediction of the efficacy of therapy prescribed for the prevention of VT/VF recurrences. To the extent that this goal is achieved, such therapy would also be expected to prevent sudden death. Therapies that may be assessed in this way include standard antiarrhythmic drug therapy, chronic amiodarone therapy, and electrosurgical or catheter-based ablation therapy. Nevertheless, this approach was usually used to individualize standard antiarrhythmic drug therapy. Although once the pinnacle of success in the selection of therapy for patients with VT/VF, controversy now surrounds the adequacy of therapy that has been predicted to be effective by the electropharmacological approach. Since this approach was first used, failures of predicted effective therapy manifest as sudden death have been recognized. In the era of the ICD, a remarkably effective therapy for the prevention of sudden death from VT/VF, such failures are no longer acceptable. Accordingly, most practitioners prefer ICD therapy to EP study guided antiarrhythmic drug therapy. Support for this position may be found in the data of the recently published Multicenter UnSustained Tachycardia Trial (MUSTT) [7] . In MUSTT, patients with chronic ischemic heart disease and left ventricular dysfunction (LVEF ≤ 0.40) who were found to have spontaneous, asymptomatic, nonsustained VT and inducible sustained VT/VF at an EP study were randomized to receive either a specific antiarrhythmic therapy selected by the EP study guided approach or to receive no specific antiarrhythmic drug therapy. The primary outcome variable in MUSTT was arrhythmic death or resuscitated cardiac arrest. In the untreated patient population the five-year actuarial probability of arrhythmic death or resuscitated cardiac arrest was 32%. EP study guided therapy reduced the five-year probability of arrhythmic death or resuscitated cardiac arrest to 25% (p = 0.04). However, essentially all of this benefit was enjoyed by patients whose therapy ended up being the ICD. Indeed, there was no evidence of a protective effect from antiarrhythmic drug therapy in comparison to no specific antiarrhythmic therapy at all. The five-year actuarial probabilities of arrhythmic death or resuscitated cardiac arrest were 9% for treated patients who received an early ICD (within 90 days from randomization), 32% for untreated patients, and 37% for treated patients who did not receive an ICD or who received a late ICD (after 90 days from randomization). This study represents the first randomized comparison of EP study guided antiarrhythmic drug therapy to no antiarrhythmic drug therapy. Further analysis of these results are needed to determine if they truly recommend abandoning the EP study guided approach to individualizing antiarrhythmic drug therapy for patients with a propensity to VT/VF. Meanwhile, it
